• • Median PFS improved from 3.2 to 5.6 months (HR 0.58; 95% CI 0.38-0.89; p=0.012) with TAS-102 plus bevacizumab, representing a 75% relative increase in progression-free survival, which is clinically meaningful in the refractory setting.
• • Median OS extended from 8.9 to 12.3 months (HR 0.64; 95% CI 0.42-0.98; p=0.041), translating to a 3.4-month absolute survival benefit, a substantial gain for patients with limited options.
• • DCR was significantly higher in the combination arm (67.9% vs. 46.4%; p=0.021), indicating better disease control, which is critical for symptom palliation and quality of life in late-line therapy.
• • Grade ≥3 neutropenia occurred in 23.2% of combination patients, consistent with known TAS-102 toxicity; no new safety signals were observed, supporting the feasibility of this regimen in routine practice.